Literature DB >> 18407716

Does iatrogenic scleroderma due to injection-site reaction to enfuvirtide impair absorption of the drug?

Paolo Maggi1, Raffaele Filotico, Stefano Bonora, Anna Volpe, Chiara Bellacosa, Eliana Cinori, Daniel Gonzalez de Requena, Antonio D'Avolio, Giovanni Di Perri.   

Abstract

BACKGROUND: Chronic iatrogenic scleroderma is a possible obstacle to the absorption of subcutaneously administered drugs. This study correlated the clinical and histopathological pattern of injection-site reactions (ISRs) to the pharmacokinetics of enfuvirtide in patients with HIV.
METHODS: Fourteen patients treated with an enfuvirtide-based antiretroviral regimen for a median of 45 weeks were enrolled and their ISRs were evaluated. Twelve patients with evidence of ISRs underwent cutaneous biopsies using a 4-mm punch. The maximum plasma enfuvirtide concentration (Cmax) and the area under the enfuvirtide concentration-time curve (AUC) were assessed using blood sampling.
RESULTS: Four different macroscopic patterns of ISR were identified: A--no evidence of cutaneous lesions; B--transient infiltrative lesions that auto-resolved within 24 hours; C--transient nodular lesions that auto-resolved within 7-15 days; and D--stable lesions after more than 30 days. Histological examination showed three morphological patterns: (1) acute urticaria/vasculitis-like pattern, (2) subacute pattern and (3) chronic scleroderma-like pattern. No differences among patients with the various patterns of ISRs were observed, except for a higher Cmax and AUC in patients with pattern 1.
CONCLUSIONS: These results confirm that although iatrogenic scleroderma is not related to impaired enfuvirtide absorption, higher Cmax and AUC values are observed in patients with urticaria/vasculitis-like patterns.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18407716     DOI: 10.2165/00044011-200828050-00004

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  8 in total

1.  Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.

Authors:  Mark Nelson; Keikawus Arastéh; Bonaventura Clotet; David A Cooper; Keith Henry; Christine Katlama; Jacob P Lalezari; Adriano Lazzarin; Julio S G Montaner; Mary O'Hearn; Peter J Piliero; Jacques Reynes; Benoit Trottier; Sharon L Walmsley; Calvin Cohen; Joseph J Eron; Daniel R Kuritzkes; Joep Lange; Hans-Jürgen Stellbrink; Jean-François Delfraissy; Neil E Buss; Lucille Donatacci; Cynthia Wat; Lynn Smiley; Martin Wilkinson; Adeline Valentine; Denise Guimaraes; Ralph Demasi; Jain Chung; Miklos P Salgo
Journal:  J Acquir Immune Defic Syndr       Date:  2005-12-01       Impact factor: 3.731

2.  An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients.

Authors:  Antonio D'Avolio; Mauro Sciandra; Daniel Gonzalez de Requena; Allende Ibañez; Stefano Bonora; Giovanni Di Perri
Journal:  Ther Drug Monit       Date:  2006-02       Impact factor: 3.681

3.  Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.

Authors:  Benoit Trottier; Sharon Walmsley; Jacques Reynes; Peter Piliero; Mary O'Hearn; Mark Nelson; Julio Montaner; Adriano Lazzarin; Jacob Lalezari; Christine Katlama; Keith Henry; David Cooper; Bonaventura Clotet; Keikawus Arastéh; Jean-François Delfraissy; Hans-Jürgen Stellbrink; Joep Lange; Daniel Kuritzkes; Joseph J Eron; Calvin Cohen; Tosca Kinchelow; Anne Bertasso; Emily Labriola-Tompkins; Anna Shikhman; Belinda Atkins; Laurence Bourdeau; Christopher Natale; Fiona Hughes; Jain Chung; Denise Guimaraes; Claude Drobnes; Silvia Bader-Weder; Ralph Demasi; Lynn Smiley; Miklos P Salgo
Journal:  J Acquir Immune Defic Syndr       Date:  2005-12-01       Impact factor: 3.731

4.  Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

Authors:  Adriano Lazzarin; Bonaventura Clotet; David Cooper; Jacques Reynes; Keikawus Arastéh; Mark Nelson; Christine Katlama; Hans-Jürgen Stellbrink; Jean-François Delfraissy; Joep Lange; Les Huson; Ralph DeMasi; Cynthia Wat; John Delehanty; Claude Drobnes; Miklos Salgo
Journal:  N Engl J Med       Date:  2003-05-29       Impact factor: 91.245

5.  Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.

Authors:  Russell A Ball; Tosca Kinchelow
Journal:  J Am Acad Dermatol       Date:  2003-11       Impact factor: 11.527

6.  Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

Authors:  Jacob P Lalezari; Keith Henry; Mary O'Hearn; Julio S G Montaner; Peter J Piliero; Benôit Trottier; Sharon Walmsley; Calvin Cohen; Daniel R Kuritzkes; Joseph J Eron; Jain Chung; Ralph DeMasi; Lucille Donatacci; Claude Drobnes; John Delehanty; Miklos Salgo
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

7.  Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.

Authors:  Jacob P Lalezari; Indravadan H Patel; Xiaoping Zhang; Albert Dorr; Nina Hawker; Zikia Siddique; Stanley J Kolis; Tosca Kinchelow
Journal:  J Clin Virol       Date:  2003-10       Impact factor: 3.168

8.  Cutaneous injection site reactions to long-term therapy with enfuvirtide.

Authors:  Paolo Maggi; Nicoletta Ladisa; Eliana Cinori; Andrea Altobella; Giuseppe Pastore; Raffaele Filotico
Journal:  J Antimicrob Chemother       Date:  2004-02-25       Impact factor: 5.790

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.